NCT04687631View on ClinicalTrials.gov

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

PHASE3RecruitingINTERVENTIONAL
Enrollment

508

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2027

Conditions
Colorectal CancerLiver Metastases
Interventions
DRUG

mFOLFOXIRI plus Cetuximab

cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks

DRUG

mFOLFOXIRI Plus Bevacizumab

bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER